“Pachyonychia congenita (PC) is a life-altering genetic disease which dramatically limits patients’ ability to ambulate and perform everyday functional activities,” stated Dr. Heron. “Palvella’s lead program PTX‑022 (novel, high-strength rapamycin topical formulation, optimized for dermal targeting) has significant potential to address this serious unmet need that currently has no approved treatments. I look forward to applying my background in rare diseases in supporting Palvella’s efforts to advance PTX-022 through late stage clinical development and commercialization.”
Pachyonychia Congenitia Project
Fighting for a cure. Connecting & helping patients. Empowering Research.
Footer
